PUBLISHED DATE : Feb 2023 | Pages : 159
Fill out your details & get your free sample
The Europe Monkeypox Testing Market Size, Share, & Trends Analysis Report By
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023–2025
159 Pages
39 Tables
71 Charts
3 Regions
10 Countries
24 Companies
3 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size ( 2022) | USD 18,330 THOUSAND |
| Market Size (2025) | USD 56.10 Thousand |
| CAGR (2022-2025) | (85.48) |
| Base Year | 2022 |
| Forecast Year | 2023-2025 |
| KEY VENDORS | F. Hoffmann-La Roche and Qiagen |
| Market Segments | Type, End-User, and Geography |
| Geographic Analysis | EU-5, Central and Eastern Europe, and Nordic |
| Countries Covered | Spain, France, UK, Germany, Italy, Netherlands, Portugal, Switzerland, Sweden, and Denmark |
The Europe monkeypox testing market size was valued at USD 18.33 million in 2022 and is expected to reach USD 56.10 thousand by 2025. The market to register a CAGR of (85.48)% from 2022 to 2025. Monkeypox is an outbreak that has spread rapidly, from the first case identified on 7th May 2022 in London, UK. MPXV, a zoonotic orthopox DNA virus related to the virus that causes smallpox, was first described in humans in 1970 in the Democratic Republic of Congo. Since early May 2022, more than 78,900 MPXV infections have been reported in more than 100 countries across five regions, prompting the WHO to declare MPX an “evolving threat of moderate public health concern” on 23rd June 2022. The outbreak of monkeypox created a lucrative opportunity for the diagnostic market.
As of 9th November 2022, Europe has reported more than 25,300 confirmed cases. However, confirmed monkeypox infections have been declining since mid-August 2022. More than 30% of all cases worldwide are held by Europe alone, to date, of which more than 98% of men are the most infected target population alone. About 80% of the infected men are gay men, thereby contributing to the growth of the Europe monkeypox testing market. Globally, 96.9% of all cases with the available data are male, with a median age of 34 years. Males aged 18 to 44 are disproportionately affected by this outbreak, as they account for more than 79% of cases.
Until mid-July, Europe was the epicenter of the largest and geographically most widespread monkeypox outbreak ever reported outside of endemic areas in western and central Africa. Currently, it is the second-largest region with the highest number of cases. This is attributed to increasing initiatives taken by the government to slow the spread of infection by publishing strict guidelines and measures to prevent the spread of monkeypox, increasing awareness, and increasing testing. In July 2022, the government of France launched a ‘Monkeypox Info service’ to provide information and advice to people following the WHO’s classification of the virus as a global public health emergency. Patients are immediately informed that they can be vaccinated if reserved on a privately run website, Doctolib, that many French residents use to book medical appointments. The testing has been available to private and public laboratories, clinics, and hospitals. In July 2022, Gemeentelijke Gezondheidsdienst (GGD), a Municipal Health Service, a decentralized public health organization, set up/opened separate facilities with separate rooms where people can get tested for the monkeypox virus.
Increasing cases and testing are driving the growth of the Europe monkeypox testing market. The growing development of PCR kits as a standard gold method for monkeypox virus detection is propelling the growth of the market in the country. Also, increasing collaborations among In-Vitro Diagnostic (IVD) companies to develop and launch new monkeypox test kits is driving market growth. Surprisingly, the ease in medical device regulation only specific for monkeypox encouraged the IVD companies to bring new testing kits into the market and commercialize it, with PCR kits being the gold standard method. Confirmation of MPXV infection is based on nucleic acid amplification testing (NAAT), which uses conventional or real-time PCR to detect unique viral DNA sequences and is widely used as a standard method to detect MPXV. Increasing activities among vendors are driving the Europe monkeypox testing market growth, including the following:
In addition, the growing product launches of lateral flow assay kits are expected to create lucrative opportunities for the Europe monkeypox testing market growth. Lateral flow assay is presently not preferred for monkeypox detection in the region because it may give false positive and negative results and because of its high cost. A number of rapid antibody and antigen test kits has been developed. Nanjing Synthgene Medical Technology, a China-based biomedical company, offers CE-certified rapid antibody and antigen tests at USD 1,253 and USD 438, respectively. In contrast, its MPXV Detection Kit (RT-PCR) costs around USD 144 with 24 tests, which means about USD 6 for each test.
The growing surveillance, contact tracing, and vaccine doses across the region are expected to impede market growth by a greater margin. However, it is unclear how much vaccine administrations have contributed to the slowdown in case numbers, and it is also unclear how long vaccine effects will last. In July 2022, the European Commission approved the MPX preventative vaccine, recommended by the European Medicines Agency (EMA).
Bavarian Nordic, a global leader in smallpox vaccines, has been a long-term supplier of the Imvanex vaccine to the US Government and has already supplied the vaccine in the European Union (EU) to many different, often unnamed, European countries. Bavarian Nordic is focused on developing, manufacturing, and commercializing human vaccines. Imvanex vaccine has been authorized to protect adults from MPX disease in the EU since 22nd July 2022.
Since the time of vaccine approval, the region has been ramping up to supply vaccine doses to every country dealing with the highest number of cases. Vaccine administration and contact tracing have rapidly increased in Spain, the second country after the US, with the highest number of confirmed cases since June 2022. On 20th October 2022, National Health Service (NHS) launched a new online vaccine site finder to make it easy for eligible people to vaccinate.
In 2022, EU-5 accounted for the largest share of 77.71% in the Europe monkeypox testing market. In EU-5, Spain accounts for the highest revenue share, followed by France, UK, Germany, and Italy, which can be attributed to increasing cases, and increased testing. More than 98% of cases are identified in men who have sex with men in EU-5. The Netherlands is vaccinating high-risk people against MPX using two doses of the Imvanex smallpox vaccine. Until 3rd August 2022, 1,976 people in the Netherlands received a preventive vaccination against the MPXV.
In Berlin, Germany, vaccinations against the viral infection had begun in mid-July. In July, The Standing Commission on Vaccination (Stiko) recommended this for certain groups and people who have had close contact with infected persons. It sees an increased risk of infection, particularly among men who have same-sex sexual contact with changing partners. According to the Senate Department for Health, demand for the MPX vaccine is very high in Berlin; however, the vaccine is still in very short supply. The shortage in vaccine supply has increased the chances of spreading MPX, which implicitly increases the possibilities of the Europe monkeypox testing market growth. However, in the future, the growing number of vaccinations for monkeypox may hinder the growth of the MPX testing market. In addition, as the currently authorized vaccine, Imvanex is not authorized for children and pregnant women, the growth of MPX testing still holds growth opportunities during the forecast period. Also, an increase in risky behavior may cause a resurgence of the virus that may keep the opportunity for MPX testing market demand.
Frequently Asked Questions
How big is the Europe monkeypox testing market?
The Europe monkeypox testing market size was valued at USD 18,330.00 thousand in 2022 and is expected to reach USD 56.10 thousand by 2025.
What is the projected growth rate of the Europe monkeypox testing market during the forecast period?
The Europe monkeypox testing market is expected to witness a declining CAGR of -85.48% during the forecast period.
What are the growing trends in the Europe monkeypox testing market?
Growing development of rapid testing methods, advancements in PCR technology, and increasing collaborations among the vendors are the growing trends in the Europe monkeypox testing market.
Which region holds the largest Europe monkeypox testing market share?
In 2022, EU-5 accounted for the largest Europe monkeypox testing market share of 77.71%. In the EU-5 region, Spain accounted for the highest revenue share attributed to increased cases and testing.
Which are the key players in the Europe monkeypox testing market?
F. Hoffmann-La Roche and Qiagen are the key companies in the Europe monkeypox testing market.
The Europe monkeypox testing market was valued at USD 18,330.00 thousand in 2022 and is expected to reach USD 56.10 thousand by 2025.
The following factors are likely to contribute to the growth of the Europe monkeypox testing market during the forecast period:
Base Year: 2022
Forecast Year: 2023-2025
The report considers the present scenario of the Europe monkeypox testing market and its market dynamics for 2023−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.
Key Company Profiles
Other Prominent Vendors
Segmentation By Type
Segmentation By Region
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY TYPE
4.3.2 MARKET SEGMENTATION BY END-USER
4.3.3 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 PREMIUM INSIGHTS
6.1 OVERVIEW
7 MARKET AT A GLANCE
8 INTRODUCTION
8.1 OVERVIEW
9 MARKET OPPORTUNITIES & TRENDS
9.1 DEVELOPMENT OF RAPID TESTING METHODS
9.2 ADVANCES IN PCR TECHNOLOGY
9.3 VENDOR COLLABORATIONS
10 MARKET GROWTH ENABLERS
10.1 INCREASED GOVERNMENT SURVEILLANCE
10.2 EASE OF REGULATIONS FOR PRODUCT APPROVALS
10.3 INCREASED PRODUCT LAUNCHES
11 MARKET RESTRAINTS
11.1 DECLINE IN MPX CASES
11.2 MPX VACCINE APPROVAL & ACCESS
11.3 FALSE MPX TEST RESULTS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.1.1 INSIGHTS BY TYPE
12.1.2 INSIGHTS BY END-USER
12.1.3 INSIGHTS BY GEOGRAPHY
12.2 FIVE FORCES ANALYSIS
12.2.1 THREAT OF NEW ENTRANTS
12.2.2 BARGAINING POWER OF SUPPLIERS
12.2.3 BARGAINING POWER OF BUYERS
12.2.4 THREAT OF SUBSTITUTES
12.2.5 COMPETITIVE RIVALRY
13 TEST TYPE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 PCR
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 LATERAL FLOW ASSAYS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.5 OTHERS
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
14 END-USER
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 LABORATORIES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 HOSPITALS & CLINICS
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 OTHERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
15 GEOGRAPHY
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
16 EU-5
16.1 MARKET OVERVIEW
16.2 MARKET SIZE & FORECAST
16.3 KEY COUNTRIES
16.3.1 SPAIN: MARKET SIZE & FORECAST
16.3.2 FRANCE: MARKET SIZE & FORECAST
16.3.3 UK: MARKET SIZE & FORECAST
16.3.4 GERMANY: MARKET SIZE & FORECAST
16.3.5 ITALY: MARKET SIZE & FORECAST
17 CENTRAL, EASTERN & SOUTHERN EUROPE
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.3 KEY COUNTRIES
17.3.1 NETHERLANDS: MARKET SIZE & FORECAST
17.3.2 PORTUGAL: MARKET SIZE & FORECAST
17.3.3 SWITZERLAND: MARKET SIZE & FORECAST
18 NORDICS
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.3 KEY COUNTRIES
18.3.1 SWEDEN: MARKET SIZE & FORECAST
18.3.2 DENMARK: MARKET SIZE & FORECAST
19 COMPETITIVE LANDSCAPE
19.1 COMPETITION OVERVIEW
19.2 MARKET SHARE ANALYSIS
19.2.1 F. HOFFMANN-LA ROCHE
19.2.2 QIAGEN
20 KEY COMPANY PROFILES
20.1 F. HOFFMANN-LA ROCHE
20.1.1 BUSINESS OVERVIEW
20.1.2 PRODUCT OFFERINGS
20.1.3 KEY STRATEGIES
20.1.4 KEY STRENGTHS
20.1.5 KEY OPPORTUNITIES
20.2 QIAGEN
20.2.1 BUSINESS OVERVIEW
20.2.2 PRODUCT OFFERINGS
20.2.3 KEY STRATEGIES
20.2.4 KEY STRENGTHS
20.2.5 KEY OPPORTUNITIES
21 OTHER PROMINENT VENDORS
21.1 ALTONA DIAGNOSTICS
21.1.1 BUSINESS OVERVIEW
21.1.2 PRODUCT OFFERINGS
21.2 AUTOBIO
21.2.1 BUSINESS OVERVIEW
21.2.2 PRODUCT OFFERINGS
21.3 APPLIED DNA SCIENCES
21.3.1 BUSINESS OVERVIEW
21.3.2 PRODUCT OFFERINGS
21.4 AURORA BIOMED
21.4.1 BUSINESS OVERVIEW
21.4.2 PRODUCT OFFERINGS
21.5 BIOACTIVA DIAGNOSTICA
21.5.1 BUSINESS OVERVIEW
21.5.2 PRODUCT OFFERINGS
21.6 BEIJING HOTGEN BIOTECH
21.6.1 BUSINESS OVERVIEW
21.6.2 PRODUCT OFFERINGS
21.7 BIOGX
21.7.1 BUSINESS OVERVIEW
21.7.2 PRODUCT OFFERINGS
21.8 CERTEST BIOTEC
21.8.1 BUSINESS OVERVIEW
21.8.2 PRODUCT OFFERINGS
21.9 CREATIVE BIOGENE
21.9.1 BUSINESS OVERVIEW
21.9.2 PRODUCT OFFERINGS
21.10 CORDX
21.10.1 BUSINESS OVERVIEW
21.10.2 PRODUCT OFFERINGS
21.11 CLONIT
21.11.1 BUSINESS OVERVIEW
21.11.2 PRODUCT OFFERINGS
21.12 EUROBIO SCIENTIFIC
21.12.1 BUSINESS OVERVIEW
21.12.2 PRODUCT OFFERINGS
21.13 FIREGENE
21.13.1 BUSINESS OVERVIEW
21.13.2 PRODUCT OFFERINGS
21.14 GENSCRIPT
21.14.1 BUSINESS OVERVIEW
21.14.2 PRODUCT OFFERINGS
21.15 GUANGZHOU PLUSLIFE BIOTECH
21.15.1 BUSINESS OVERVIEW
21.15.2 PRODUCT OFFERINGS
21.16 JOYSBIO (TIANJIN) BIOTECHNOLOGY
21.16.1 BUSINESS OVERVIEW
21.16.2 PRODUCT OFFERINGS
21.17 NANJING SYNTHGENE MEDICAL TECHNOLOGY
21.17.1 BUSINESS OVERVIEW
21.17.2 PRODUCT OFFERINGS
21.18 RAYBIOTECH LIFE
21.18.1 BUSINESS OVERVIEW
21.18.2 PRODUCT OFFERINGS
21.19 SANSURE BIOTECH
21.19.1 BUSINESS OVERVIEW
21.19.2 PRODUCT OFFERINGS
21.20 VIRAX BIOLABS
21.20.1 BUSINESS OVERVIEW
21.20.2 PRODUCT OFFERINGS
21.21 WONDFO
21.21.1 BUSINESS OVERVIEW
21.21.2 PRODUCT OFFERINGS
21.22 SHANGHAI BIOGERM MEDICAL TECHNOLOGY
21.22.1 BUSINESS OVERVIEW
21.22.2 PRODUCT OFFERINGS
22 REPORT SUMMARY
22.1 KEY TAKEAWAYS
22.2 STRATEGIC RECOMMENDATIONS
23 QUANTITATIVE SUMMARY
23.1 MARKET BY GEOGRAPHY
23.2 MARKET BY TYPE
23.3 MARKET BY END-USER
24 APPENDIX
24.1 ABBREVIATIONS
EXHIBIT 1 SEGMENTATION OF EUROPE MONKEYPOX TESTING MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
EXHIBIT 3 TESTING ALGORITHM FOR MPX VIRUS
EXHIBIT 4 IMPACT OF DEVELOPMENT OF RAPID TESTING METHODS
EXHIBIT 5 POPULAR RAPID TEST KITS
EXHIBIT 6 IMPACT OF ADVANCES IN PCR TECHNOLOGY
EXHIBIT 7 IMPACT OF VENDOR COLLABORATIONS
EXHIBIT 8 IMPACT OF INCREASED GOVERNMENT SURVEILLANCE
EXHIBIT 9 IMPACT OF EASE OF REGULATIONS FOR PRODUCT APPROVALS
EXHIBIT 10 IMPACT OF INCREASED PRODUCT LAUNCHES
EXHIBIT 11 IMPACT OF DECLINE IN MPX CASES
EXHIBIT 12 IMPACT OF MPX VACCINE APPROVAL & ACCESS
EXHIBIT 13 GLOBAL QUARTER SALES OF IMVANEX, 2022 ($ MILLION)
EXHIBIT 14 IMPACT OF FALSE MPX TEST RESULTS
EXHIBIT 15 GROWTH CURVE OF MPX CASES IN EUROPE AS OF NOVEMBER 7, 2022
EXHIBIT 16 PERCENT DISTRIBUTION OF DATA TYPE IN EUROPE AS OF NOVEMBER 9, 2022
EXHIBIT 17 EUROPE MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 18 EUROPE MONKEYPOX TESTING MARKET BY TYPE 2022–2025 (%)
EXHIBIT 19 EUROPE MONKEYPOX TESTING MARKET BY END-USER 2022–2025 (%)
EXHIBIT 20 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY 2022–2025 (%)
EXHIBIT 21 FIVE FORCES ANALYSIS 2022
EXHIBIT 22 INCREMENTAL GROWTH BY TYPE 2022 & 2025
EXHIBIT 23 EUROPE MONKEYPOX TESTING MARKET BY TYPE
EXHIBIT 24 EUROPE MONKEYPOX TESTING MARKET BY TYPE: INCREMENTAL GROWTH ($ THOUSAND)
EXHIBIT 25 EUROPE MONKEYPOX TESTING MARKET BY TYPE: ABSOLUTE GROWTH (%)
EXHIBIT 26 EUROPE MONKEYPOX TESTING MARKET BY PCR 2022–2025 ($ THOUSAND)
EXHIBIT 27 EUROPE MONKEYPOX TESTING MARKET BY PCR: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 28 EUROPE MONKEYPOX TESTING MARKET BY LATERAL FLOW ASSAYS 2022–2025 ($ THOUSAND)
EXHIBIT 29 EUROPE MONKEYPOX TESTING MARKET BY LATERAL FLOW ASSAYS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 30 EUROPE MONKEYPOX TESTING MARKET BY OTHERS 2022–2025 ($ THOUSAND)
EXHIBIT 31 EUROPE MONKEYPOX TESTING MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 32 INCREMENTAL GROWTH BY END-USER 2022 & 2025
EXHIBIT 33 EUROPE MONKEYPOX TESTING MARKET BY END-USER
EXHIBIT 34 EUROPE MONKEYPOX TESTING MARKET BY END-USER: INCREMENTAL GROWTH ($ THOUSAND)
EXHIBIT 35 EUROPE MONKEYPOX TESTING MARKET BY END-USER: ABSOLUTE GROWTH (%)
EXHIBIT 36 EUROPE MONKEYPOX TESTING MARKET BY LABORATORIES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 EUROPE MONKEYPOX TESTING MARKET BY LABORATORIES 2022–2025 ($ THOUSAND)
EXHIBIT 38 EUROPE MONKEYPOX TESTING MARKET BY HOSPITALS & CLINICS 2022–2025 ($ THOUSAND)
EXHIBIT 39 EUROPE MONKEYPOX TESTING MARKET BY HOSPITALS & CLINICS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 40 NEW PRODUCT LAUNCHES
EXHIBIT 41 EUROPE MONKEYPOX TESTING MARKET BY OTHERS 2022–2025 ($ THOUSAND)
EXHIBIT 42 EUROPE MONKEYPOX TESTING MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 43 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2025
EXHIBIT 44 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY
EXHIBIT 45 NUMBER OF MPX CASES IN EUROPEAN COUNTRIES AS OF NOVEMBER 9, 2022
EXHIBIT 46 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY: INCREMENTAL GROWTH ($ THOUSAND)
EXHIBIT 47 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY: ABSOLUTE GROWTH (%)
EXHIBIT 48 EUROPE MONKEYPOX TESTING MARKET: KEY COUNTRIES 2022 ($ THOUSAND)
EXHIBIT 49 NUMBER OF MPX CASES IN EU-5 AS OF NOVEMBER 9, 2022
EXHIBIT 50 EU-5 MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 51 EU-5 MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 INCREMENTAL GROWTH IN EU-5 2022 & 2025
EXHIBIT 53 SPAIN MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 54 FRANCE MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 55 UK MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 56 GERMANY MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 57 ITALY MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 58 TOP COUNTRIES WITH MPX CASES IN CENTRAL, EASTERN & SOUTHERN EUROPE AS OF NOVEMBER 9, 2022
EXHIBIT 59 CENTRAL, EASTERN & SOUTHERN EUROPE MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 60 CENTRAL, EASTERN & SOUTHERN EUROPE MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 61 INCREMENTAL GROWTH IN CENTRAL, EASTERN & SOUTHERN EUROPE 2022 & 2025
EXHIBIT 62 NETHERLANDS MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 63 PORTUGAL MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 64 SWITZERLAND TOTAL MONKEYPOX CASES AS OF NOVEMBER 7, 2022
EXHIBIT 65 SWITZERLAND MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 66 TOP NORDIC COUNTRIES WITH MPX CASES AS OF NOVEMBER 9, 2022
EXHIBIT 67 NORDICS MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 68 NORDICS MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 69 INCREMENTAL GROWTH IN NORDICS 2022 & 2025
EXHIBIT 70 SWEDEN MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
EXHIBIT 71 DENMARK MONKEYPOX TESTING MARKET 2022–2025 ($ THOUSAND)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015–2022
TABLE 3 MOLECULAR TECHNIQUES FOR NUCLEIC ACID DETECTION
TABLE 4 IMMUNOLOGICAL METHODS FOR ANTIBODY OR ANTIGEN DETECTION
TABLE 5 TOTAL MPX CASES AMONG MEN FROM DIFFERENT CATEGORIES AS OF NOVEMBER 9, 2022
TABLE 6 RECENT MONKEYPOX TEST LAUNCHES
TABLE 7 SUMMARY OF MONKEYPOX CASES AS OF NOVEMBER 8, 2022
TABLE 8 NEWLY LAUNCHED PCR KITS WITH CE CERTIFICATION
TABLE 9 COMPANIES THAT OFFER LATERAL FLOW ASSAY KITS
TABLE 10 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 11 QIAGEN: MAJOR PRODUCT OFFERINGS
TABLE 12 ALTONA DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 13 AUTOBIO: MAJOR PRODUCT OFFERINGS
TABLE 14 APPLIED DNA SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 15 AURORA BIOMED: MAJOR PRODUCT OFFERINGS
TABLE 16 BIOACTIVA DIAGNOSTICA: MAJOR PRODUCT OFFERINGS
TABLE 17 BEIJING HOTGEN BIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 18 BIOGX: MAJOR PRODUCT OFFERINGS
TABLE 19 CERTEST BIOTEC: MAJOR PRODUCT OFFERINGS
TABLE 20 CREATIVE BIOGENE: MAJOR PRODUCT OFFERINGS
TABLE 21 CORDX: MAJOR PRODUCT OFFERINGS
TABLE 22 CLONIT: MAJOR PRODUCT OFFERINGS
TABLE 23 EUROBIO SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 24 FIREGENE: MAJOR PRODUCT OFFERINGS
TABLE 25 GENSCRIPT: MAJOR PRODUCT OFFERINGS
TABLE 26 GUANGZHOU PLUSLIFE BIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 27 JOYSBIO (TIANJIN) BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 28 NANJING SYNTHGENE MEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 29 RAYBIOTECH LIFE: MAJOR PRODUCT OFFERINGS
TABLE 30 SANSURE BIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 31 VIRAX BIOLABS: MAJOR PRODUCT OFFERINGS
TABLE 32 WONDFO: MAJOR PRODUCT OFFERINGS
TABLE 33 SHANGHAI BIOGERM MEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 34 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY 2022–2025 ($ THOUSAND)
TABLE 35 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY 2022–2025 (%)
TABLE 36 EUROPE MONKEYPOX TESTING MARKET BY TYPE 2022–2025 ($ THOUSAND)
TABLE 37 EUROPE MONKEYPOX TESTING MARKET BY TYPE 2022–2025 (%)
TABLE 38 EUROPE MONKEYPOX TESTING MARKET BY END-USER 2022–2025 ($ THOUSAND)
TABLE 39 EUROPE MONKEYPOX TESTING MARKET BY END-USER 2022–2025 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
